In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
At the AACR Annual Meeting, Sharpless said NCI should focus on improving early screening, access to trials, and development of advanced drugs to realize President Biden's goal of eradicating cancer.
PanCAN has invested $25 million in the study, which will screen blood samples from new-onset diabetes patients for biomarkers associated with pancreatic cancer.
